Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cellectar Biosc (CLRB)

Cellectar Biosc (CLRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,455
  • Shares Outstanding, K 40,567
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,980 K
  • EBIT $ -48 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.88

Options Overview Details

View History
  • Implied Volatility 411.89% ( +277.31%)
  • Historical Volatility 38.98%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 411.89% on 11/18/24
  • IV Low 25.03% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,332
  • Volume Avg (30-Day) 284
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 4,906
  • Open Int (30-Day) 3,734

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.43
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +58.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.66 +6.63%
on 11/18/24
2.20 -19.55%
on 11/11/24
-0.32 (-15.31%)
since 10/18/24
3-Month
1.66 +6.63%
on 11/18/24
2.29 -22.71%
on 08/30/24
-0.26 (-12.81%)
since 08/16/24
52-Week
1.66 +6.63%
on 11/18/24
4.45 -60.22%
on 03/04/24
-0.31 (-14.90%)
since 11/17/23

Most Recent Stories

More News
Cellectar Biosciences Announces Phase 2 CLOVER-WaM Study Data Selected for Presentation at ASH Meeting and Financial Results for Q3 2024

Cellectar Biosciences announced Phase 2 study results and fundraising efforts, preparing for NDA submission for iopofosine I 131.Quiver AI SummaryCellectar Biosciences, Inc. announced significant advancements...

CLRB : 1.77 (-4.84%)
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

CLRBZ : 0.12 (-14.27%)
CLRB : 1.77 (-4.84%)
CLRBW : 0.13 (+348.28%)
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

CLRB : 1.77 (-4.84%)
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

CLRB : 1.77 (-4.84%)
Cellectar Reports Financial Results for Second Quarter 2022

FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the...

CLRB : 1.77 (-4.84%)
Cellectar Announces Stock Consolidation

FLORHAM PARK, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the...

CLRB : 1.77 (-4.84%)
Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

FLORHAM PARK, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...

CLRB : 1.77 (-4.84%)

Business Summary

Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in...

See More

Key Turning Points

3rd Resistance Point 2.22
2nd Resistance Point 2.08
1st Resistance Point 1.93
Last Price 1.77
1st Support Level 1.64
2nd Support Level 1.50
3rd Support Level 1.35

See More

52-Week High 4.45
Fibonacci 61.8% 3.38
Fibonacci 50% 3.06
Fibonacci 38.2% 2.73
Last Price 1.77
52-Week Low 1.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar